GRT-R910: a self-amplifying mRNA SARS-CoV-2 vaccine boosts immunity for ≥6 months in previously-vaccinated older adults.

Comparatively, 100%, 42.9%, 85.7%, 25%, and 28.6% of participants had positive responses 6 months following GRT-R910 administration to TCE pools Nuc OLP, Mem OLP, ORF3a OLP, Nuc Min, and ORF3a Min, respectively, though increases did not reach statistical significance ( p > 0.05, Chi-Square test; Fig. 5C ).

also in 111,027 other papers